Physician profile
Subbu J Sarma
NPI 1689661829
$150,444.62
in general payments reported to CMS, 2019-2025
32 companies · $45K in 2025
The $45K reported for 2025 was more than what 99% of Addiction Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $152).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $972 · 2020: $190 · 2021: $955 · 2022: $6,494 · 2023: $45K · 2024: $52K · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $116K · Travel and Lodging: $15K · Food and Beverage: $11K · Education: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $116,104.50 |
| Travel and Lodging | $14,884.67 |
| Food and Beverage | $10,585.87 |
| Education | $257.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $121,560.98 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| E.R. Squibb & Sons, L.L.C. | $13,417.14 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $7,188.47 | 2023-2024 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $1,192.61 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $1,056.46 | 2019-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $736.69 | 2022-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $732.98 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $714.90 | 2019-2025 | Rexulti |
| Abbvie INC. | $695.08 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $641.85 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $586.32 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $423.87 | 2019-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $421.44 | 2021-2025 | Fanapt, Hetlioz |
| Corium, LLC | $142.05 | 2022-2024 | Azstarys |
| Acadia Pharmaceuticals INC | $123.96 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $122.11 | 2023-2025 | Xelstrym |
| Merck Sharp & Dohme LLC | $111.67 | 2022-2023 | Belsomra |
| Indivior INC. | $95.82 | 2019-2023 | Perseris |
| Allergan, INC. | $74.11 | 2019-2020 | |
| Almatica Pharma LLC | $59.68 | 2024 | Loreev Xr |
| Shire North American Group INC | $47.91 | 2019 | |
| Tris Pharma INC | $46.57 | 2022-2024 | Dyanavel Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $42.27 | 2019 | |
| Supernus Pharmaceuticals, INC. | $41.10 | 2023-2024 | Qelbree, Qelbree |
| Jazz Pharmaceuticals INC. | $34.01 | 2021-2022 | |
| Neos Therapeutics, Lp | $30.01 | 2023 | Adzenys Xr-Odt |
| Biogen, INC. | $27.61 | 2025 | Zurzuvae |
| Janssen Scientific Affairs, LLC | $24.95 | 2024-2025 | Invega Sustenna |
| Sage Therapeutics, LLC | $14.57 | 2019 | |
| Eisai INC. | $13.49 | 2020 | |
| Ironshore Pharmaceuticals INC. | $12.95 | 2023 | Jornay Pm |
| Neuronetics, INC. | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subbu Sarma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.